Theratechnologies To Develop Tesamorelin For The Treatment Of Nash In The General Population
Theratechnologies To Develop Tesamorelin For The Treatment Of Nash In The General Population
Sep 10, 2020
Supporting Materials:
Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021
Clinical study to include HIV cohort
Montreal, Canada – September 10, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the general population.